BRIEF-Viracta Therapeutics Says Complete Responses Observed Across Multiple Ebv+ Lymphoma Subtypes In Phase 2 Study

Reuters
07 Dec 2020

Dec 7 (Reuters) - Viracta Therapeutics :

* VIRACTA THERAPEUTICS - COMPLETE RESPONSES OBSERVED ACROSS MULTIPLE EBV+ LYMPHOMA SUBTYPES IN PHASE 2 STUDY

* VIRACTA THERAPEUTICS - REGISTRATION TRIAL FOR TREATMENT OF RELAPSED/REFRACTORY EBV+ LYMPHOMAS TO BEGIN IN 1H2021

* VIRACTA THERAPEUTICS - END OF PHASE 2 MEETING WITH UNITED STATES FDA TO ADDRESS CHEMISTRY, MANUFACTURING AND CONTROLS IS PLANNED FOR DEC 2020

Source :

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10